The term ultra-LABA indicates once-daily β2-AR agonists (abediterol, indacaterol, olodaterol
and vilanterol) that are single enantiomers of the (R)-configuration. All have a near full …

Evaluation of the role of adrenergic agents as bronchodilators started at the beginning of the
century. In 1900, Solis-Cohen discovered a bronchodilator substance derived from the …

Objective To review the pharmacology of the long-acting inhaled β 2-agonists, salmeterol
and formoterol, summarize results of their clinical trials, evaluate their safety records, and …

The use of a regular long-acting β 2-adrenoceptor agonists (β 2-agonists; LABA) is now
established in asthma guidelines as the preferred option for second-line controller therapy in …

Bronchodilators are central in the symptomatic management of asthma. It is likely that the
once-daily dosing of a bronchodilator would be a significant convenience and probably a …

Several studies suggested an association between the regular use of β 2-agonists and
asthma deaths. Whether this association represents adverse effects of β-agonist use or is …

Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists,
are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The …

The safety of long-acting β2-agonist (LABA) treatment in asthma has been questioned
following reported increased respiratory deaths when salmeterol was added to usual …

Long-acting β 2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in
the treatments of chronic obstructive lung diseases. Although no specific indications …

The design and profile of a series of indole containing long acting β2-adrenoceptor agonists
is described. Evaluation of these analogues using an in vitro guinea pig trachea tissue …